Revisiting Non-Cancer Drugs for Cancer Therapy

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• Cancer incidence and mortality rates are rising, outpacing traditional anticancer drug development.
• Anticancer drug development faces challenges including dose-limiting toxic side effects and lengthy, expensive processes.
• Existing drugs, especially non-cancer medications, possess established safety profiles, making them valuable candidates for repurposing.

Purpose of the Study:

• To review recent advancements and examples of drug repositioning for cancer therapy.
• To highlight the potential of utilizing existing non-cancer drugs in preclinical and clinical cancer treatment settings.
• To underscore the cost- and time-effectiveness of drug repositioning in oncology.

Main Methods:

• Literature review of recent studies on drug repositioning in cancer therapy.
• Analysis of examples involving existing non-cancer drugs being investigated for anticancer applications.
• Focus on preclinical and clinical stages of repurposed drug introduction.

Main Results:

• Drug repositioning is an increasingly recognized strategy in cancer research.
• Numerous non-cancer drugs have demonstrated potential for anticancer efficacy.
• Repurposed drugs offer a faster and more economical route to new cancer therapies.

Conclusions:

• Drug repositioning of existing non-cancer drugs is a promising avenue for developing novel cancer therapies.
• This approach effectively mitigates the challenges associated with traditional drug development, such as toxicity and cost.
• Further exploration of repurposed drugs is crucial for advancing cancer treatment options.